Paratek Pharmaceuticals, Inc. (PRTK) News

Paratek Pharmaceuticals, Inc. (PRTK): $1.97

-0.09 (-4.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRTK to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter PRTK News Items

PRTK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PRTK News Highlights

  • For PRTK, its 30 day story count is now at 4.
  • Over the past 7 days, the trend for PRTK's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • SA and VALE are the most mentioned tickers in articles about PRTK.

Latest PRTK News From Around the Web

Below are the latest news stories about Paratek Pharmaceuticals Inc that investors may wish to consider to help them evaluate PRTK as an investment opportunity.

What Is The Ownership Structure Like For Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)?

If you want to know who really controls Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ), then you'll have to look at the...

Yahoo | February 8, 2022

Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ...

Investment company Kalos Management, Inc. (Current Portfolio) buys Vale SA, sells Consensus Cloud Solutions Inc, Intuitive Surgical Inc, Amarin Corp PLC, Catalyst Biosciences Inc, Paratek Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Kalos Management, Inc..

Yahoo | February 3, 2022

AGF Investments LLC Buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The ...

Investment company AGF Investments LLC (Current Portfolio) buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The Energy Select Sector SPDR Fund, Paratek Pharmaceuticals Inc, Hello Group Inc, sells Industrial Select Sector SPDR, Consumer Staples Select Sector SPDR, Utilities Select Sector SPDR ETF, Microsoft Corp, UnitedHealth Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, AGF Investments LLC.

Yahoo | February 2, 2022

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on January 31, 2022, the Company granted stock options to six new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, In

Yahoo | February 1, 2022

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel Sells $21,551.92 in Stock

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 4,876 shares of the companys stock in a transaction dated Monday, December 13th. The shares were sold at an average price of $4.42, for a total transaction of $21,551.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Dakota Financial News | December 18, 2021

Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Insider Sells 4,479 Shares of Stock

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) insider Randall B. Brenner sold 4,479 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, December 13th. The stock was sold at an average price of $4.42, for a total transaction of $19,797.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which []

Transcript Daily | December 18, 2021

Randall B. Brenner Sells 15,780 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) insider Randall B. Brenner sold 15,780 shares of the firms stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $4.27, for a total value of $67,380.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. []

Dakota Financial News | December 17, 2021

William M. Haskel Sells 17,178 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 17,178 shares of Paratek Pharmaceuticals stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $4.27, for a total value of $73,350.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Transcript Daily | December 17, 2021

China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin Infections

Paratek earns $6 million milestone payment from Zai LabBOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company’s partner in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), received approval from the National Medical Products Administration (NMPA) of China of NUZYRA® (omadacycline) for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek commerciall

Yahoo | December 16, 2021

Investors in Paratek Pharmaceuticals (NASDAQ:PRTK) from five years ago are still down 67%, even after 11% gain this past week

This week we saw the Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) share price climb by 11%. But that doesn't change...

Yahoo | December 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.48 seconds.